News

Changes in gut bacteria may be linked to Parkinson’s disease and can vary with age, disease severity, and medications, but more research is needed to understand whether these changes actually contribute to how symptoms develop and progress, a study suggests. “These findings regarding the relationships between microbial communities…

Practicing Tai Chi four times a week may lessen motor symptoms and improve physical function and quality of life in people with early- to mid-stage Parkinson’s disease, a small clinical trial found. A program combining resistance and stretching exercises produced similar overall improvements in motor symptoms, but each approach…

The U.S. Food and Drug Administration (FDA) has awarded fast-track designation — a status that aims to speed the development of promising treatments for serious conditions — to a Swiss biopharmaceutical company for an experimental vaccine designed to slow or prevent neurodegeneration in people with early Parkinson’s disease. The…

People with early Parkinson’s disease who received the oral therapy bezisterim in a Phase 2 clinical trial saw significant improvements in a measure of symptom severity compared with patients given a placebo, top-line results showed. Trial results also showed that bezisterim was generally tolerated well and that the therapy…

A commercially available oral cannabis oil — containing two natural compounds found in the plant, one with psychoactive properties — appeared to be generally safe for people with Parkinson’s disease, but failed to reduce pain or ease other symptoms among participants in a small mid-stage clinical trial. The tested…

An off-the-shelf, or ready to use, stem cell therapy that’s designed to replace the nerve cells lost in Parkinson’s disease and restore neurological function has been put on a developmental fast track by the U.S. Food and Drug Administration (FDA). The FDA awarded fast track status — a designation…

Risvodetinib, an oral therapy Abli Therapeutics is developing for people with Parkinson’s disease, reduced multiple disease-related biomarkers, the company announced. The findings come from an expanded analysis of the 201 Phase 2 study (NCT05424276), which enrolled patients with bradykinesia (slowed movement), a hallmark symptom of Parkinson’s. The trial tested…